Monopar rises after FDA grants rare pediatric disease status to Wilson disease drug

Monopar Therapeutics

30/06/2026 13:13

** Shares of biotech firm Monopar Therapeutics MNPR.O rise 5% to $99 premarket
** Co says FDA granted rare pediatric disease designation to its experimental drug ALXN1840 for Wilson disease, a rare inherited disorder that causes toxic copper buildup in the body
** Monopar says the designation could qualify the company for a priority review voucher if the drug is approved
** Says such vouchers can be used to speed review of another medicine or be sold to other drugmakers
** Co's ALXN1840, a once-daily oral tablet, removed copper more effectively than current treatments in a late-stage study over 48 weeks
** Adds that the treatment showed a favorable safety profile in the study
** As of last close, stock up ~45% YTD

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))